Idogen publishes interim report for 1 January – 31 March 2022
Idogen AB's interim report for January to March 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/
First quarter (January-March 2022)
• Other operating income amounted to KSEK 0 (1,679)
• Operating loss was KSEK -10,712 (-10,651)
• Loss for the quarter totalled KSEK -10,692 (-10,531)
• Cash flow from operating activities was KSEK -18,061 (-9,952)
• Loss per share before dilution was SEK -0.25 (-0.58). Loss per share after dilution was SEK -0.25 (-0.58)
Significant events in the first quarter
• Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.
• Idogens Idogen’s Chief Scientific Officer, Åsa Schiött, presented the company’s tolerogenic cell therapy platform at the 5th Antigen-Specific Immune Tolerance Summit.
• Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from 15 May. • Idogen’s rights issue raise MSEK 41 after issue costs.
• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.
Significant events after the end of the period
• Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8-program.
• Idogen strengthens the organization with key competencies for the clinical development phase.
• No other significant events occurred after the end of the period that affected the results or financial position.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 (0)70 918 00 10
Email: anders.karlsson@idogen.com
Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se
The information was submitted for publication, through the agency of the contact persons set out above, on May 4, 2022 at 08:18 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com